Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
TAG Mail 23 November 2016 The purpose of TAG Mail is to assist TAG members identify and share relevant information for their professional practice. Members are encouraged to routinely forward TAG Mail to others who they believe would benefit from this information such as colleagues in the same hospital department if they are not already receiving TAG Mail. TAG ACTIVITIES ** NSW TAG Life Saving Drugs Registers - The Life Saving Drugs Register - Antivenoms 2016 will be uploaded to the website today. These Antivenom and Antidote registers are used by NSW hospitals, hospitals of other jurisdictions, retrieval services and Poisons Information Centres across Australia to provide 24-hour assistance in location of antidote and antivenom stocks. As such, when NSW TAG has not received stock information from a hospital, the hospital will be listed with a ‘NO DETAILS PROVIDED’ notation. Hospitals which do not stock antidotes or antivenoms will also be identified. For facilities that have not yet responded please provide details using the following link https://www.surveymonkey.com/r/antivenom2016 ** Margaret Jordan is attending the Anticoagulant Medicines Working Party at the Clinical Excellence Commission (CEC) on Friday 25 November. The NOAC guidelines are published on the CEC website http://www.cec.health.nsw.gov.au/__data/assets/pdf_file/0007/326419/noac_guidelines.pdf The working party is now developing guidance for the management of antithrombotic agents in the perioperative period. For more information, please contact Margaret ([email protected]) TAG WEBSITE **CIAP - CIAP has disabled the following forms on the NSW TAG website: http://www.ciap.health.nsw.gov.au/nswtag/about/contact.html http://www.ciap.health.nsw.gov.au/nswtag/about/how-to-apply.html Please contact NSW TAG via email [email protected] or by calling 02 8382 2852. CONSULTATIONS **TGA - Consultation: Orphan drug program- 2015 consultation outcomes and 2016 orphan drug program proposal. Closes Friday 25 November 2016. http://www.tga.gov.au/consultation/consultation-orphan-drug-program - Consultation: Software as a Medical Device (SaMD) Clinical evaluation. Closes 2 December 2016 http://www.tga.gov.au/consultation/consultation-software-medical-device-samd-clinical-evaluation REPORTS AND PUBLICATIONS – AUSTRALIA **AIHW - Emergency department care 2015-16: Australian hospital statistics http://www.aihw.gov.au/publication-detail/?id=60129557372 **NPS MedicineWise - NPS Direct October 2016 http://www.nps.org.au/health-professionals/e-newsletters/nps-direct/2016/october **NSW Health - Neonatal – Jaundice Identification and Management in Neonates > 32 Weeks Gestation http://www0.health.nsw.gov.au/policies/gl/2016/GL2016_027.html **TGA - Recall: Kaiser Pharmaceutical Traditional Chinese Medicine Products – potential for adverse events relating to aristolochic acid(s). http://www.tga.gov.au/alert/kaiser-pharmaceutical-traditional-chinese-medicine-products - Registration of new prescription medicines: --Ixazomib (NinlaroTM) for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma who have received at least one prior therapy. --Alpha 1-proteinase inhibitor (Prolastin CTM) indicated to increase serum Alpha 1-PI levels in adults with congenital deficiency of alpha-1 antitrypsin and with clinically significant emphysema (FEV1<80%). http://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia - AusPAR added: Netupitant/Palonosetron (Akynezo TM) for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic and of moderately emetogenic cancer chemotherapy in adults. http://www.tga.gov.au/auspar/auspar-netupitant-palonosetron-hydrochloride - AusPAR added: Selexipag (UptraviTM) for patients with WHO functional class II, III or IV symptoms for the treatment of idiopathic pulmonary arterial hypertension; heritable pulmonary arterial hypertension; pulmonary arterial hypertension associated with connective tissue disease/congenital heart disease with repaired shunts/ with drugs and toxins. http://www.tga.gov.au/auspar/auspar-selexipag - AusPAR added: Tenofovir disoproxil fumarate/emtricitabine (TruvadaTM) now also indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce risk of sexually acquired HIV-1 in adults at high risk. http://www.tga.gov.au/auspar/auspar-tenofovir-disoproxil-fumarate-emtricitabine - AusPAR added: Secukinumab (CosentyxTM / ZafrezTM) for the treatment of adult patients with active psoriatic arthritis when the response to previous disease-modifying anti rheumatic drug (DMARD) therapy inadequate, and for the treatment of adult patients with active ankylosing spondylitis. http://www.tga.gov.au/auspar/auspar-secukinumab-1 - Updates to the prescribing medicines in pregnancy database: Six newly registered medicines added and 65 previously registered medicines added. http://www.tga.gov.au/updates-prescribing-medicines-pregnancy-database REPORTS AND PUBLICATIONS – INTERNATIONAL **EMA - EPAR added: Lenvatinib (KisplyxTM) for the treatment of adults with advanced renal cell carcinoma http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004224/human _med_002021.jsp&mid=WC0b01ac058001d124 **ISMP Is an indication-based prescribing system in our future? http://www.ismp.org/newsletters/acutecare/showarticle.aspx?id=1153 **NICE -Intrapartum care for healthy women and babies https://www.nice.org.uk/guidance/cg190 MEDICATION SAFETY **NSW Health - Implantable cardiac defibrillator and cardiac resynchronization therapy defibrillator devices http://www.health.nsw.gov.au/sabs/Documents/2016-sn-013.pdf **MHRA - Brimonidine gel (Mirvaso): risk of exacerbation of rosacea https://www.gov.uk/drug-safety-update/brimonidine-gel-mirvaso-risk-of-exacerbation-of-rosacea **NHS Patient Safety Alert: Risk of severe harm and death due to withdrawing insulin from pen devices https://improvement.nhs.uk/news-alerts/risk-severe-harm-and-death-withdrawing-insulin-pendevices/ PAPERS OF INTEREST **AJHP - ASHP Foundation Pharmacy Forecast 2017: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems http://www.ajhp.org/content/early/2016/11/18/sp170001?papetoc - Meta-analysis of ascorbic acid for prevention of postoperative atrial fibrillation after cardiac surgery http://www.ajhp.org/content/early/2016/11/15/ajhp160066 - Evaluation of a protocol to optimize duration of pneumonia therapy at hospital discharge http://www.ajhp.org/content/early/2016/11/15/ajhp160011 - Precision medicine in oncology: New practice models and roles for oncology pharmacists http://www.ajhp.org/content/73/23/1935.abstract?etoc - Implementation of inpatient models of pharmacogenetics programs http://www.ajhp.org/content/73/23/1944.abstract?etoc -Integrating pharmacogenomics into electronic health records with clinical decision support http://www.ajhp.org/content/73/23/1967.abstract?etoc - Evidence and resources to implement pharmacogenetic knowledge for precision medicine http://www.ajhp.org/content/73/23/1977.abstract?etoc - Educational strategies to enable expansion of pharmacogenomics-based care http://www.ajhp.org/content/73/23/1986.abstract?etoc **Annals of Internal Medicine - A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement http://annals.org/aim/article/2587367/reporting-tool-practice-guidelines-health-care-rightstatement **BMJ - Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study http://www.bmj.com/content/355/bmj.i5813 - Management of mild hypertension in adults http://www.bmj.com/content/355/bmj.i5719 ** Canadian Medical Association Journal - Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation http://www.cmaj.ca/content/early/2016/11/21/cmaj.160303 **Cochrane Library - Drug therapies for reducing gastric acidity in people with cystic fibrosis http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD003424.pub4/full - Steroid avoidance or withdrawal for kidney transplant recipients http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD005632.pub3/full -Pharmacological interventions for pruritus in adult palliative care patients http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008320.pub3/abstract;jsessionid=264FF92C 44A674EED5B0CFD70375FEA4.f03t02 **JAMA -Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients, The GLAGOV Randomized Clinical Trial http://jamanetwork.com/journals/jama/fullarticle/2584184 **JAMA Internal Medicine - Association of 3 Different Antihypertensive Medications with Hip and Pelvic Fracture Risk in Older Adults: Secondary Analysis of a Randomized Clinical Trial http://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2587085 **Journal of Clinical Oncology - Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients with Advanced Melanoma http://ascopubs.org/doi/abs/10.1200/JCO.2015.66.1389 **MJA - Antimicrobial use in Australian hospitals: how much and how appropriate? https://www.mja.com.au/journal/2016/205/10/antimicrobial-use-australian-hospitals-how-muchand-how-appropriate -Nocebo effects in practice: methotrexate myths and misconceptions https://www.mja.com.au/journal/2016/205/10/nocebo-effects-practice-methotrexate-myths-andmisconceptions **NEJM - Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease http://www.nejm.org/doi/full/10.1056/NEJMoa1602773 - Palbociclib and Letrozole in Advanced Breast Cancer http://www.nejm.org/doi/full/10.1056/NEJMoa1607303 **Paediatrics - Intravenous versus Oral Antibiotics for Post-discharge Treatment of Complicated Pneumonia http://pediatrics.aappublications.org/content/early/2016/11/15/peds.2016-1692 **The Lancet -Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31651-8/fulltext -Intratympanic methylprednisolone versus gentamicin in patients with unilateral Ménière's disease: a randomised, double-blind, comparative effectiveness trial http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31461-1/fulltext UPCOMING EVENTS (new additions in bold) **2nd Digital Hospital of the Future, ANZ 2016 ‘Improving Patient Care Delivery and Monitoring with Digital Technology Innovations and Transformation’ 7th-9th December 2016, InterContinental Sydney Australia http://claridenglobal.com/conference/digitalhospital2016/?utm_campaign=L6285_Digital%20Hospita l_AU_EDM%202_Buy&utm_medium=email&utm_source=Eloqua **Australian Society for Antimicrobials Adelaide. 23 - 25 February and 25 - 26 February 2017 Abstract Submission Deadline: Friday, 9 December 2016 www.antimicrobials2017.com ** 10th Pharmaceutical Care Network Europe (PCNE) Working Conference ‘Lead – Engage- Disseminate’ 1 - 4 February 2017 in Bled, Slovenia. http://www.pcne.org/conference/23/10th-pcne-working-conference-2017 **ISMP CHA Medication Safety Intensive, Sydney, March 9-10 2017. Early bird ends 31 October 2016 https://children.wcha.asn.au/ismp_medsafety **CADTH Symposium, April 23, 2017 - April 25, 2017: Shaw Centre, Ottawa, Ontario https://www.cadth.ca/events/2017-cadth-symposium **2017 NSW Patient Experience Symposium, 1st-2nd May 2017 Bay 4, Australian Technology Park, Eveleigh NSW http://www.alignmentevents.com.au/sh_events/2017-nsw-patient-experience-symposium-call-forabstracts/#1473648903182-6aa8fa3c-649b You are receiving this email because you or a workplace colleague has requested TAG Mail. NSW TAG analyses uptake of TAG Mail (email openings and clicks on specific contents) in order to optimise the TAG Mail service for our members and colleagues. By requesting TAG Mail, you are also agreeing to have your data (email address, country of abode) captured. All information obtained is used in accordance with NSW Health Privacy Policy. Please contact NSW TAG at [email protected] if you have any questions regarding this.